

## REFERENCE LIST

### REFERENCES

#### SODIUM SALICYLATE

- 1) Abdallah H Y et al, The influence of age on salicylate pharmacokinetics in humans. *J Clin Pharmacol*, 1991; 31: 380-387.
- 2) Altman R D, Salicylates in the treatment of arthritic disease. How safe and effective? *Postgrad Med*, 1988; 84: 206-210.
- 3) Boettcher F A et al, Concentration of salicylate in serum and perilymph of the chinchilla. *Arch Otolaryngol Head Neck Surg*, 1990; 116: 681-684.
- 4) Bosetti C et al, Aspirin and the risk of prostate cancer. *Eur J Cancer Prev*, 2006; 15:43-45.
- 5) Brune K, Biodistribution of salicylates: A clue to the understanding of some effects and side effects. *Agents Actions*, 1977; 7: 163-177.
- 6) Brune K et al, Parietal cells of the stomach trap salicylates during absorption. *Biochem Pharmacol*, 1977; 26: 1735-1740.
- 7) Cerletti C et al, Plasma levels of salicylic acid and aspirin in healthy volunteers: Relevance to drug interaction on platelet function. *J Lab Clin Med*, 1984; 103: 869-877.
- 8) Chen X et al, Sodium salicylate triggered apoptosis in HL-60 cells depends on caspase 8 activation. *Int J Haematol*, 2002; 75: 407-411.
- 9) Chernoff N and Rogers J M, Supernumerary ribs in development toxicity bioassays and in human populations: incidence and biological significance. *J Toxicol Environ Health*, 2004; 7: 437-449.
- 10) Cosmetic Ingredient Review Expert Panel, Safety assessment of salicylates. *Int J Toxicol*, 2003; 22 Suppl 3: 1-108.
- 11) Davis D P et al, Maternal reproductive effects of oral Salicylic acid in Sprague Dawley rats. *Toxicol Lett*, 1996; 84: 135-141.
- 12) Davis W B et al, Hydroxylation of salicylates by activated neutrophils. *Biochem Pharmacol*, 1989; 38: 4013-4019.
- 13) Dean M et al, The pharmacokinetics of salicylate in pregnant Wistar rats. *Drug metab Dispos*, 1989; 17: 87-90.
- 14) Didier A et al, The vascular component of sodium salicylate ototoxicity in the guinea pig. *Hear Res*, 1993; 69: 199-206.
- 15) Dromgoole S H et al, Rational approaches to the use of salicylates in the treatment of rheumatoid arthritis. *Sem Arthrit Rheumat*, 1981; 11: 257-283.
- 16) Elis J et al, The distribution of sodium salicylate in the human foetus. *Int J Clin Pharmacol Biopharm*, 1978; 16: 365-367.
- 17) Eriksson M and Larsson K S, Influence of low protein diet on salicylate induced damage in mice. *Biol Neonate*, 1982; 41: 138-142.
- 18) Farrow D C et al, Use of aspirin and other NSAIDs and risk of oesophageal and gastric cancers. *Cancer Epidemiol Biomarkers Prev*, 1998; 7: 97-102.
- 19) Fleming H et al, Sodium salicylate centrally augments ventilation through cholinergic mechanisms. *J Appl Physiol*, 1991; 71: 2299-2303.
- 20) Foulon O et al, Induction of SNR with sodium salicylate. *Reprod Toxicol*, 1999; 13: 369-374.
- 21) Francis B M et al, Effects of murine cytomegalovirus on development, lack of interaction of virus and sodium salicylate. *J Appl Toxicol*, 1990; 10: 43-46.

- 22) Fritz H and Suter H P, Postnatal development of young rats following the treatment of the dams with sodium salicylate during the late stages of pregnancy. *Arzneimittelforschung*, 1985; 35: 937-939.
- 23) Furst D E, Clinically important interactions of NSAIDs with other medications. *J Rheumatol*, 1988; 15: suppl 17: 58-62.
- 24) Giri A K et al, Comparative genotoxicity of 6 salicylic acid derivatives in bone marrow cells of mice, *Mutat Res Genet Toxicol*. 1996; 370: 1-9.
- 25) Graham G G and Scott K F, Mechanisms of action of paracetamol and related analgesics. *Inflammopharmacology*, 2003; 11: 401-413.
- 26) Greenaway J C et al, Embryotoxic effects of salicylates: Role of biotransformation. *Toxicol Appl Pharmacol*, 1984; 74: 141-149.
- 27) Gulamhusein A P et al, Salicylate induced teratogenesis in the ferret. *Life Sci*, 1980; 27: 1799-1805.
- 28) Higgs G A and Salmon J A, Is aspirin a pro-drug for salicylate. In *Aspirin and other salicylates*. Ed Vane J R and Botting R M, Chapman and Hall; 1992: 63-73.
- 29) Jones M K et al, Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. *Nat Med*, 1999; 5: 1348-1349.
- 30) Kajii H et al, Effects of salicylic acid on the permeability of the plasma membrane of the small intestine of the rat. A fluorescence spectroscopic approach to elucidate the mechanism of promoted drug absorption. *J Pharm Sci*, 1986; 75: 475-478.
- 31) Karabulut A K et al, Protection by free oxygen radical scavenging enzymes against salicylate induced embryonic malformations in vitro. *Toxicol in vitro*, 2000; 14: 297-307.
- 32) Kopp E and Ghosh S, Inhibition of NF kappa B by sodium salicylate and aspirin. *Science*, 1995; 270: 2017-2019.
- 33) Kurowski M and Brune K, Other unwanted side effects and drug interaction with aspirin and other salicylates. In *Aspirin and other salicylates*. Ed Vane J R and Botting R M, Chapman and Hall; 1992: 576-600.
- 34) Kyle M E and Koesis J J, The effect of age on salicylate induced nephrotoxicity in male rats. *Toxicol Appl Pharmacol*, 1985; 81: 337-347.
- 35) Leonards J R and Levy G, Gastrointestinal blood loss from aspirin and sodium salicylate tablets in man. *Clin Pharmacol Ther*, 1973; 14: 62-66.
- 36) Levy G, Clinical pharmacokinetics of salicylates: a re-assessment. *Brit J Clin Pharmacol*, 1980; 10: 285S-290S.
- 37) Lucas J C et al, Intrauterine growth retardation after long term maternal salicylate administration in the rabbit. *Am J Obstet Gynecol*, 1987; 156: 245-249.
- 38) Martindale, 32nd edition, 1999
- 39) Miaskiewicz S L et al Sex differences in the absorption kinetics of sodium salicylate. *Clin Pharmacol Ther*, 1982; 31: 30-37.
- 40) Mills D G et al, The effects of some salicylate analogues on human blood platelets. Structure activity relationships and the inhibition of platelet aggregation. *Life Sci*, 1974; 14: 659-672.
- 41) Nanra R S, Renal effects of antipyretic analgesics. *Am J Med*, 1983; 75: 70-81
- 42) Netter P et al, Salicylate kinetics in old age. *Clin Pharmacol Ther*, 1985; 38: 6-11
- 43) Nishihata T et al, Possible mechanisms of uptake for several compounds in ionised form through human erythrocyte membrane. *Life Sci*, 1984; 34: 427-436.
- 44) Potter J D, Colorectal cancer: molecules and populations. *J Natl Cancer Inst*, 1999; 91: 916-932.
- 45) Qiao L et al, Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. *Biochem Pharmacol*, 1998; 55: 53-64.

- 46) Quintanilla A and Kessler R H, Direct effects of salicylate on renal function in the dog. *J Clin Invest*, 1973; 52: 3143-3153.
- 47) Record I R and Dreosti I E, Zinc and riboflavin interactions with salicylate in pregnant rats. *Nutr Rep Int*, 1988; 38: 1041-1048.
- 48) Reimann I W et al, Influence of intravenous acetyl salicylic acid and sodium salicylate on human renal function and lithium clearance. *Eur J Clin Pharmacol*, 1985; 29: 435-441.
- 49) Roch-Ramel F et al, Salicylate excretion in the rat. Free flow micropuncture experiments. *J Pharmacol Exp Ther*, 1979; 207: 737-747.
- 50) Rowe P H et al, Parenteral aspirin and sodium salicylate are equally injurious to the rat gastric mucosa. *Gastroenterology*, 1987; 93: 863-871.
- 51) Rubin A et al, Interaction of aspirin with NSAIDs in man. *Arthritis Rheum*, 1973; 16: 635-645.
- 52) Sairam K et al, Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenylpyridinium induced dopaminergic neurotoxicity in rats. *Brain Res*, 2003; 21: 245-252.
- 53) Schreinemachers D M and Everson R B, Aspirin use and lung, colon, and breast cancer incidence in a prospective study. *Epidemiology*, 1994; 5: 138-146.
- 54) Seymour R A et al, The efficacy and pharmacokinetics of sodium salicylate in post-operative dental pain. *Br J Clin Pharmacol*, 1984; 17: 161-163.
- 55) Short C R et al, Elimination of salicylic acid in goats and cattle. *Am J Vet Res*, 1990; 51: 1267-1270.
- 56) Silva P R et al, respiratory and acid base parameters during salicylic intoxication in dogs. *Braz J Med Biol Res*, 1986; 19: 279-286.
- 57) Simmons D L and Wilson J E, Apoptosis induced with NSAIDs. In *Therapeutic roles of selective COX 2 inhibitors*. Ed Vane J R and Botting R M, William Harvey Press, 2001; 221-251.
- 58) Suzuka T et al, The effects of salicylate concentration on the uptake of salicylate and ceftnetazole in rat isolated small intestinal epithelial cells. *J Pharm Pharmacol*, 1988; 40: 469-472
- 59) Talbodec A et al, Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. *Mol Pharmacol*, 2000; 57: 797-804.
- 60) Tariq M et al, Attenuation of Iminodipropionitrile induced behavioural syndrome by sodium salicylate in rats. *Paharmacol Biochem Behav*, 2002; 73: 647-654.
- 61) Tageder I et al, Cyclooxygenase independent actions of cyclooxygenase inhibitors. *FASEB*, 2001; 15: 2057-2072.
- 62) Thaller J et al, The effect of NSAIDs on spinal fusion. *Orthopaedics*, 2005; 28: 299-303.
- 63) Varma D R and Yue T L, Influence of age, sex, pregnancy and protein calorie malnutrition on the pharmacokinetics of salicylate in rats. *Br J Pharmacol*, 1984; 82: 241-248.
- 64) Wery N et al, Vertebral malformations induced by sodium salicylate correlate with shifts in expression domains of Hox genes. *Reprod Toxicol*, 2005; 20: 39-45.
- 65) Wu D and Cederbaum A I, Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes. *Mol Pharmacol*, 2001; 59: 795-805.

## VITAMIN C

- 66) Akatov V S et al, Combined vitamins B12 and C induce the glutathione depletion and the death of epidermoid human larynx carcinoma cells HEp-2. *Biosci Rep*, 2000; 20: 411-417.
- 67) Anderson R, Ascorbic acid and immune function: mechanism of immune stimulation. *Vitamin C*, 1981; Applied Science Publishers: 249-272.
- 68) Bachleitner H T et al, Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia. *Br J Haematol*, 2001; 112: 783-786.
- 69) Basu T K and Dickerson J W T, *Vitamins in Health and Disease*. CAB International, 1996; 125-147.
- 70) Bendich A and Langseth L, The health effects of vitamin C supplementation: A review. *J Am Coll Nutr*, 1995; 14: 124-136.
- 71) Bjelakovic G et al, Anti-oxidant supplements for prevention of gastrointestinal cancers: A systematic review and meta-analysis. *Lancet*, 2004; 364: 1219-1228.
- 72) Buc C P et al, Potential therapeutic application of the association of vitamins C and K3 in cancer treatment. *Curr med Chem*, 2002; 9: 2271-2285.
- 73) Bussey H J et al, A randomised trial of ascorbic acid in polyposis coli. *Cancer*, 1982; 50: 1434-1439
- 74) Byers T and Guerrero N, Epidemiological evidence for vitamin C and vitamin E in cancer prevention. *Am J Clin Nutr*, 1995; 62: 1385S-1392S.
- 75) Cameron E and Pauling L, Supplemental ascorbate in the supportive treatment of cancer. Prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci USA*, 1976; 73: 3685-3689.
- 76) Cameron E, Protocol for the use of vitamin C in the treatment of cancer. *Med Hypotheses*, 1991; 36: 190-194.
- 77) Cameron E and Campbell A, Innovation vs quality control: an unpublished clinical trial of supplemental ascorbate in incurable cancer. *Med Hypotheses*, 1991; 36: 185-189.
- 78) Carr A C and Frei B, Toward a new recommended dietary allowance for vitamin C based on anti-oxidant and health effects in humans. *Am J Clin Nutr*, 1999; 69: 1086-1087.
- 79) Chan S W and reade P C, The role of ascorbic acid in oral cancer and carcinogenesis. *Oral Dis*, 1998; 4: 120-129.
- 80) Connelly A E et al, Vitamin C intake and apoptosis in normal rectal epithelium. *Cancer Epidemiol Biomarkers Prev*. 2003; 12: 559-565.
- 81) Correa P et al, Chemoprevention of gastric dysplasia: randomised trial of anti-oxidant supplements and anti-Helicobacter pylori therapy. *J Natl Cancer Inst*, 2000; 92: 1881-1888.
- 82) Creagan E T et al, failure of high dose vitamin C therapy to benefit patients with advanced cancer: a controlled trial. *N Eng J Med*, 1979; 301: 687-690.
- 83) Drisko J A et al, The use of anti-oxidants with first line chemotherapy in 2 cases of ovarian cancer. *J Am Coll Nutr*, 2003; 22: 118-123.
- 84) Duarte T L and Lunec J, Review: When is an anti-oxidant not a anti-oxidant? A review of novel actions and reactions of vitamin C. *Free Radic Res*, 2005; 39: 671-686.
- 85) Dyke G W et al, Effect of vitamin C supplementation on gastric mucosal DNA damage. *Carcinogenesis*, 1994; 15: 291-295.
- 86) Ekstroem A M et al, Dietary anti-oxidant intake and the risk of cardia cancer and oncardia cancer of the intestinal and diffuse types: apopulation based control study in Sweden. *Int J Cancer*, 2000; 87: 133-140.
- 87) Enstrom J E et al, Vitamin C intake and mortality among a sample of the United States population. *Epidemiology*, 1992; 3: 194-202

- 88) Feiz H R and Mobarhan S, Does vitamin C intake slow the progression of gastric cancer in H pylori infected populations. *Nutr Rev*, 2002; 60: 34-36.
- 89) Flagg E W et al, Epidemiological studies of anti-oxidants and cancers in humans. *J Am Coll Nutr*, 1995; 14: 419-427.
- 90) Fletcher R H and Fairfield K M, Vitamins for chronic disease prevention in adults: Clinical applications. *J Am Med Assoc*, 2002; 287: 3127-3129.
- 91) Fleischauer A T et al, Dietary anti-oxidants, supplements, and risk of epithelial ovarian cancer. *Nutr Cancer*, 2001; 40: 92-98.
- 92) Fraga C U, Ascorbic acid protects against endogenous oxidative DNA damage in human sperm. *Proc Natl Acad Sci*, 1991; 8: 11003
- 93) Galan P et al, Anti-oxidant status and risk of cancer in the SU.VI.MAX study: Is the effect of supplementation dependant on baseline levels. *Br J Nutr*, 2005; 94: 125-132.
- 94) Goel S et al, Emerging role of ascorbic acid in the management of advanced breast cancer as a chemosensitiser. *Asian J Surg*, 1999; 22: 333-336.
- 95) Greco A M et al, Study of blood vitamin C in lung and bladder cancer patients before and after treatment with ascorbic acid. *Acta Vitaminol Enzymol*, 1982; 4: 155-162.
- 96) Head K A, Ascorbic acid in the prevention and treatment of cancer. *Altern Med Rev*, 1998; 3: 174-186.
- 97) Hathcock J N, Vitamins and minerals: Efficacy and safety. *Am J Clin Nutr*, 1997; 66: 427-437.
- 98) Hornig D et al, Absorption of large, single oral intakes of ascorbic acid. *Int J Vit Nutr Res.*, 1980; 50: 309-314.
- 99) Horn-Ross P L et al, Diet and the risk of salivary gland cancer. *Am J Epidemiol*, 1997; 146: 171-176
- 100) Jacobs E J et al, Vitamin C, vitamin E and multivitamin supplement use and stomach cancer mortality in the Cancer Prevention Study II cohort. *Cancer Epidemiol Biomarkers Prev*, 2002; 11: 35-41.
- 101) Jaffey M, Vitamin C and cancer: examination of the Vale of Leven trial results using broad inductive reasoning. *Med Hypotheses*, 1982; 8: 49-84.
- 102) Jialal I and Fuller C J, Effect of vitamin E, vitamin C and beta carotene on LDL oxidation and atherosclerosis. *Can J Cardiol*, 1995; 11: 97G-103G.
- 103) Kim D S et al, Effect modification by vitamin C on the relation between gastric cancer and Helicobacter pylori, *Eur J Epidemiol*, 2005; 20: 67-71.
- 104) Kurbacher C M et al, Ascorbic acid improves the anti-neoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. *Cancer Lett*, 1996; 103: 183-189.
  
- 105) Levine M et al, Vitamin C pharmacokinetics in healthy volunteers. Evidence for a recommended daily allowance. *Proc Natl Acad Sci USA*, 1996; 93: 3704-3709.
- 106) Levine M et al, Vitamin C. In: Present knowledge and nutrition. Ed Filer L J and Ziegler EE. International Life Sciences Institute. 1996a, 146-159.
- 107) Kushi L H et al, Intake of vitamins A, C and E and post menopausal breast cancer. The Iowa Womens health study. *Am J Epidemiol*, 1996; 144: 165-174
- 108) La Vecchia C et al, Vegetables, fruit, anti-oxidants and cancer. A review of Italian studies. *Eur J Nutr*, 2001; 40: 261-267.
- 109) Iamm D L et al. Megadose vitamins in bladder cancer: a double blind clinical trial. *J Urol*, 1994; 151: 21-26.
- 110) Lamson D W and Brignall M S, Anti-oxidants and cancer therapy: their actions and interactions with oncologic therapies. *Altern Med Rev*, 1999; 4: 304-329.

- 111) Lee K W et al, Vitamin C and cancer chemoprevention: Reappraisal. *Am J Clin Nutr*, 2003; 78: 1074-1078.
- 112) Lesperance M L et al, Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: An historical cohort study. *Breast Cancer Res Treat*, 2002; 76: 137-143.
- 113) Levine M et al, Vitamin C pharmacokinetics in healthy volunteers. Evidence for a recommended daily allowance. *Proc Natl Acad Sci USA*, 1996; 93: 3704-3709.
- 114) Michels K B et al, Dietary anti-oxidant vitamins, retinol, and breast cancer incidence in a cohort of Swedish women. *Int J Cancer*, 2001; 91: 563-567.
- 115) Moertel C G et al, High dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no previous chemotherapy. A randomised double blind comparison. *N Eng J Med*, 1985; 312: 137-141.
- 116) Murata A et al, Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. *Int J Vitamin Nutr Res Suppl*, 1982; 23: 103-113.
- 117) Nienhuis A W, Vitamin C and iron. *N Eng J Med*, 1981; 304: 170-171.
- 118) Osmak M et al, Ascorbic acid and 6-Cl-AA: Potential anti-cancer drugs. *Neoplasma*, 1997; 44: 101-107.
- 119) Padayatty S J et al, Vitamin C as an anti-oxidant. Evaluation of its role in disease prevention. *J Am Coll Nutr*, 2003; 22: 18-35.
- 120) Padayatty S J et al, Vitamin C pharmacokinetics: Implications for oral and intravenous use. *Ann Int Med*, 2004; 140: 533-537.
- 121) Paganelli G M et al, Effect of vitamin A, C and E supplementation on rectal cell proliferation in patients with colorectal adenomas. *J Natl cancer Inst*, 1992; 84: 47-51.
- 122) Pathak-Ashutosh K et al, Chemotherapy alone vs chemotherapy plus high dose multiple oxidants in patients with advanced non small cell lung cancer. *J Am Coll Nutr*, 2005; 24: 16-21.
- 123) Poulter J M et al, Ascorbic acid supplementation and 5 year survival rates in women with early breast cancer. *Acta Vitaminol Enzymol*, 1984; 6: 175-182.
- 124) Reddy V G et al, Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilising P53. *Biochem Biophys Res Commun*, 2001; 282: 409-415.
- 125) Rees D C et al, Acute haemolysis induced by high dose ascorbic acid in glucose 6-phosphate dehydrogenase deficiency. *Br Med J*, 1993; 306: 841-842.
- 126) Riordan N H et al, Intravenous ascorbate as a tumour cytotoxic chemotherapeutic agent. *Med Hypotheses*, 1995; 44: 207-213.
- 127) Roncucci L et al, Anti-oxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. *Dis Colon Rectum*, 1993; 36: 227-234.
- 128) Ruffin M T and Rock C L, Do anti-oxidants still have a role in the prevention of human cancer. *Curr Oncol Rep*, 2001; 3: 306-313.
- 129) Sasaki S et al, Effects of 3 month oral supplementation of beta-carotene and vitamin C on serum concentrations of carotenoids and vitamins in middle aged subjects. *Jpn J Cancer Res*, 2000; 91: 464-470.
- 130) Sasazuki S et al, The effect of 5 year vitamin C supplementation on serum pepsinogen level and Helicobacter pylori infection. *Cancer Sci*, 2003; 94: 378-382.
- 131) Sies H and Stahl W, Vitamins E and C, beta carotene and other carotenoids as anti-oxidants. *Am J Clin Nutr*, 1995; 62: 1315S-1321S.
- 132) Stipanuk M H, *Biochemical and Physiological Aspects of Human Nutrition*. W B Saunders; 2000; 542-567.
- 133) Tannenbaum S R et al, Inhibition of nitrosamine formation by ascorbic acid. *Am J Clin Nutr*, 1991; 53: 247S-250S.

- 134) Taper H S et al, In vivo reactivation of DNases in implanted human prostate tumours after administration of a vitamin C/K3 combination. *J Histochem Cytochem*, 2001; 49: 109-120.
- 135) Terry P et al, Anti-oxidants and cancers of the oesophagus and gastric cardia. *Int J Cancer*, 2000; 87: 750-754.
- 136) Tsao C S et al, In vivo antineoplastic activity of ascorbic acid for human mammary tumour. *In Vivo*, 1988; 2: 147-150.
- 137) Urivetzky M et al, Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis. *J Urol*, 1992; 147: 1215-1218.
- 138) Verhoeven D T et al, Vitamins C and E, beta-carotene and dietary fibre in relation to breast cancer risk: a prospective cohort study. *Br J Cancer*, 1997; 75: 149-155
- 139) Vermeer I T et al, Effect of ascorbic acid and green tea on endogenous formation of N-nitrosodimethylamine and N-nitrosopiperidine in humans. *Mutat Res*, 1999; 428: 353-361.
- 140) Verrax J et al, The association of vitamins C and K3 kills cancer cells mainly by autophagy, a novel form of cell death. Basis for their potential use as adjuvants in anticancer therapy. *Eur J Med Chem*, 2003; 38: 451-457.
- 141) Virtamo J, Vitamins and lung cancer. *Proc Nutr Soc*, 1999; 58: 329-333.
- 142) Weber P et al, Vitamin C and human health-a review of recent data relevant to human requirements. *Int J Vitam Nutr Res*, 1996; 66: 19-30.
- 143) Weiji N I et al, Supplementation with anti-oxidant micronutrients and chemotherapy induced toxicity in cancer patients treated with cisplatin based chemotherapy; a randomised, double blind, placebo controlled study. *Eur J Cancer*, 2004; 40: 1713-1723.
- 144) Welch R W et al, Accumulation of Vitamin C and its oxidised metabolite occurs by separate mechanisms. *J Biol Chem*, 1995; 270: 12584-12592.
- 145) White K L M et al, Dietary anti-oxidants and DNA damage in patients on long term acid suppression therapy. A randomised controlled study, 2002; 88: 265-271.
- 146) Zhang-Schumin M, Role of vitamins in the risk, prevention and treatment of breast cancer. *Curr Opin Obstet Gynecol*, 2004; 16: 19-25.
- 147) Zullo A et al, Ascorbic acid and intestinal metaplasia in the stomach: a prospective randomised study. *Aliment Pharmacol Ther*, 2000; 14: 1303-1309.

## MANGANESE

- 148) Ali S F et al, Mn induced reactive species: Comparison between Mn<sup>2+</sup> and Mn<sup>3+</sup>. *Neurodegeneration*, 1995; 4: 329-334.
- 149) Analyst-Internet Health Report, Feb, 2006.
- 150) Andersen M E et al, Pharmacokinetic data needs to support risk assessments for inhaled and ingested Mn. *Neurotoxicology*, 1999; 20: 161-171.
- 151) Arnich N et al, Comparative in situ study of the intestinal absorption of aluminium, manganese, nickel and lead in rats. *Biol Trace Elem Res*, 2004; 99: 157-171.
- 152) Aschner M et al, Mn uptake and distribution in the CNS. *Neurotoxicology*, 1999; 20: 173-180.
- 153) Aschner M et al, Mn dosimetry, species differences and implications for neurotoxicity. *Crit Rev Toxicol*, 2005; 35: 1-32.

- 154) Barceloux D G , Manganese. *J Toxicol Clin Toxicol*, 1999; 37: 293-307.
- 155) Barhoumi R et al, Mn potentiates lipopolysaccharide induced expression of NO synthase in C6 glioma cells through mitochondrial dependant activation of nuclear factor kappaB. *Brain Res Mol Brain Res*, 2004; 122: 167-179.
- 156) Bataineh H et al, Assessment of aggression, sexual behaviour and fertility in adult male rat following long term ingestion of industrial metal salts. *Hum Exp Toxicol*, 1998; 17: 570-576.
- 157) Beach R S et al, Zinc, copper and Mn in immune function and experimental oncogenesis. *Nutr Cancer*, 1982; 3: 172-191.
- 158) Bonilla E, Chronic Mn intake induces changes in the motor activity in rats. *Exp Neurol*, 1984; 84: 696-700.
- 159) Brurok H et al, Mn and the heart: acute cardiodepression and myocardial accumulation of Mn. *Acta Physiol Scand*, 1997; 159: 33-40.
- 160) Brus R et al, Exposure of pregnant rats to Mn. Effects on levels, turnover and release of biogenic amines in brains of their offspring. *Pharmacol Rev Commun*, 2002; 12: 61-75.
- 161) Casalino E et al, Rat liver glutathione S transferase activity stimulation following acute cadmium or Mn intoxication. *Toxicology*, 2004; 200: 29-38.
- 162) Chen M T et al, Protective effects of Mn against lipid peroxidation. *J Toxicol Environ Health A*, 2000; 61: 569-577.
- 163) Chen M T et al, Brain lipid peroxidation and changes of trace metals in rats following chronic Mn chloride exposure. *J Toxicol Environ Health A*, 2002; 65: 305-316.
- 164) Colomina M T et al, Effect of the day of exposure on the development toxicity of Mn in mice. *Vet Hum Toxicol*, 1996; 38: 7-9.
- 165) Crossgrove J S et al, Mn distribution across the blood brain barrier. Evidence for carrier mediated influx of Mn citrate as well as Mn and Mn transferrin. *Neurotoxicology*, 2003; 24: 3-13.
- 166) Davidsson L et al, Mn absorption from human milk, cows milk and infant formulae in humans. *Am J Dis Child*, 1989; 143: 823-827.
- 167) Davidsson L et al, Mn retention in man: a method for estimating Mn absorption in man. *Am J Clin Nutr*, 1989a; 49: 170-179.
- 168) Davidsson L et al, The effect of individual dietary components on Mn absorption in humans. *Am J Clin Nutr*, 1991; 54: 1065-1070.
- 169) Daviddson L et al, Mn absorption in humans, the effect of phytic acid and ascorbic acid in soy formula. *Am J Clin Nutr.*, 1995; 62: 984-987.
- 170) Davis C D et al, Mn metabolism in rats: an improved methodology for assessing gut endogenous losses. *Proc Soc Exp Biol Med*, 1993; 202: 103-108.
- 171) Davis C D et al, Varying levels of Mn and Fe affect absorption and gut endogenous losses of Mn by rats. *J Nutr*, 1992; 122: 1300-1308.
- 172) Davis C D and Feng Y, Dietary Cu, Mn and Fe affect the formation of aberrant crypts in colon of rats administered 3,2 dimethyl 4 aminobiphenyl. *J Nutr*, 1999; 129: 1060-1067.
- 173) Desoize B, Metals and metal compounds in carcinogenesis. *In Vivo*, 2003; 17: 529-539.
- 174) Dickinson T K et al, Distribution of injected iron 59 and Mn 54 in hypotransferrinemic mice. *J Lab Clin Med*, 1996; 128: 270-278.
- 175) Donaldson J et al, Mn neurotoxicity, a model for free radical mediated neurodegeneration. *Can J Physiol Pharmacol*, 1984; 60: 1398-1405.
- 176) Dorman D C et al, Neurotoxicity of Mn chloride in neonatal and adult CD rats following sub-chronic high dose oral exposure. *J Appl Toxicol*, 200; 20: 179-187.

- 177) Dvoinova I et al, Potential carcinogenicity of some transition metal ions. *Biol Trace Elem Res*, 1999; 67: 63-73.
- 178) Doyle D and Kapron C M, Inhibition of cell differentiation by Mn chloride in micromass cultures of mouse embryonic limb bud cells. *Toxicol Vitro*, 2002; 16: 101-106.
- 179) Elbetieha A et al, Effects of long term exposure to Mn chloride on fertility of male and female mice. *Toxicol Lett*, 2001; 119: 193-201.
- 180) Erikson K M et al, Glutamate/aspartate transporter, taurine transporter and metallothionein mRNA levels are differentially altered in astrocytes exposed to Mn chloride, Mn phosphate or Mn sulphate. *Neurotoxicology*, 2002; 23: 281-288.
- 181) Erikson K M and Aschner M, Mn neurotoxicity and glutamate-GABA interaction. *Neurochem Int*, 2003; 43: 475-480.
- 182) Erikson K M et al, Mn exposure and oxidative stress in the rat brain. *Sci Total Environ.*, 2004; 334-335: 409-416.
- 183) Eriksson H et al, Effects of Mn oxide on monkeys as revealed by a combined neurochemical, histological and neurophysiological evaluation. *Arch Toxicol*, 1987; 61: 46-52.
- 184) Fechter L D, Distribution of Mn in development. *Neurotoxicology*, 1999; 20: 197-201.
- 185) Fechter L D et al, The relationship of particle size to olfactory nerve uptake of a non-soluble form of Mn into the brain. *Neurotoxicology*, 2002; 23: 177-183.
- 186) Finley J W, Mn uptake and release by human cultured hepato-carcinoma cells. *Biol Trace Elem Res*, 1998; 64: 101-118.
- 187) Finley J W and Davis C D, Mn deficiency and toxicity: are high or low dietary amounts of Mn cause for concern. *Biofactors*, 1999; 10: 15-24.
- 188) Finley J W, Mn absorption and retention by young women is associated with serum ferritin concentrations. *Am J Clin Nutr*, 1999; 70: 37-43.
- 189) Finley J W et al, Dietary Mn intake and type of lipid do not affect clinical or neuropsychological measures in healthy young women. *J Nutr*, 2003; 133: 2849-2856.
- 190) Finley J W, Does environmental exposure to Mn pose a health risk to healthy adults? *Nutr Rev*, 2004; 62: 148-153.
- 191) Freeland-Graves J H et al, Metabolic balance of Mn in young men consuming diets containing 5 levels of dietary Mn. *J Nutr*, 1988; 118: 764-773.
- 192) Gavin C E et al, Mn 2+ sequestration by mitochondria and inhibition of oxidative phosphorylation. *Toxicol Appl Pharmacol*, 1992; 115: 1-5.
- 193) Gerber G B et al, Carcinogenicity, mutagenicity and teratogenicity of Mn compounds. *Crit Rev Oncol Hematol*, 2002; 42: 25-34.
- 194) Gralak M A et al, Comparison of the influence of dietary fibre sources with different proportions of soluble and insoluble fibre. *Arch Tierernahr*, 1996; 49: 293-299.
- 195) Gregor J L, Dietary standards for Mn overlap between nutritional and toxicological studies. *J Nutr*, 1998; 128: 368S-371S.
- 196) Gregor J L, Nutrition versus toxicology of Mn in humans: evaluation of potential biomarkers. *Neurotoxicology*, 1999; 20: 205-212.
- 197) Gwiazda R H et al, Low cumulative Mn exposure affects striatal GABA but not dopamine. *Neurotoxicology*, 2002; 23: 69-76.
- 198) Hazell A S, Astrocytes and Mn neurotoxicity. *Neurochem Int*, 2002; 41: 271-277.
- 199) Heilig E et al, Pharmacokinetics of pulmonary Mn absorption, evidence for increased susceptibility to Mn loading in iron deficient rats. *Am J Physiol Lung Cell Mol Physiol*, 2005; 288: L887-893.
- 200) Hiraku Y et al, Metal mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. *Carcinogenesis*, 1995; 16: 349-356.

- 201) Hirata Y et al, Activation of JNK pathway and induction of apoptosis by Mn in PC12 cells. *J Neurochem*, 1998; 71: 1607-1615.
- 202) Holbrook C J et al, Studies on the evaluation of the toxicity of various salts of lead, manganese, platinum and palladium. *Environ Health Persp*, 1975; 10: 95-101.
- 203) Huang Y L et al, In vitro effects of metal ions on sperm motility and lipid peroxidation in human serum. *J Toxicol Environ Health A*, 2001; 62: 259-267.
- 204) Hudnall H K, Effects from environmental Mn exposure: a review of the evidence from non-occupational exposure studies. *Neurotoxicology*, 1999; 20: 379-397.
- 205) Joardar M and Sharma A, Comparison of the clastogenicity of inorganic Mn administered in anionic and cationic forms in vivo. *Mutat Res*, 1990; 240: 159-163. . 206) Johnson P and Korynta E D, The effect of dietary protein source on Mn bioavailability in the rat. *Proc Soc Exp Biol Med*, 1990; 195: 230-236.
- 207) Johnson P E et al, Absorption and biological half life in humans of intrinsic and extrinsic <sup>54</sup>Mn tracers from foods of plane origin. *J Nutr*, 1991; 121: 711-717.
- 208) Kazantzis G, Role of cobalt, iron, lead, Mn, mercury, platinum, selenium and titanium in carcinogenesis. *Environ Health Perspect*, 1981; 40: 143-161
- 209) Keen C L et al, Nutritional aspects of Mn from experimental studies. *Neurotoxicol*, 1999; 20: 213-223.
- 210) Khan K N et al, Toxicity of subacute intravenous MnCl<sub>2</sub> administration in beagle dogs. *Toxicol Pathol*, 1997; 25: 344-350.
- 211) Komura J and Sakamoto M, Chronic oral administration of MMT altered brain biogenic amines in the mouse: comparison with inorganic Mn. *Toxicol Lett*, 1994; 73: 65-73.
- 212) Komura J and Sakamoto M, Effects of Mn forms on biogenic amines in the brain and behavioural alterations in the mouse: long term oral administration of several Mn compounds, *Environ Res*, 1992; 57: 34-44.
- 213) Kondakis X G et al, Possible health effects of high Mn concentrations in drinking water. *Arch Environ Health*, 1989; 44: 175-178.
- 214) Kontur P J and Fechter L D, Brain Mn, catecholamine turnover, and the development of startle in rats prenatally exposed to Mn. *Teratology*, 1985; 32: 1-11.
- 215) Lai J C K et al, Differences in the neurotoxic effects of Mn during development and aging: some observations on brain regional neurotransmitter and non-neurotransmitter metabolism in a developmental rat model of chronic Mn encephalopathy. *Neurotoxicology*, 1984; 5: 37-47.
- 216) Lai J C K et al, Neurochemical changes in rats chronically treated with high concentration of Mn chloride. *Neurochem Res*, 1992; 17: 841-847.
- 217) Lansdown A B G, Physiological and toxicological changes in the skin resulting from the actions and interactions of metal ions. *Crit Rev Toxicol*, 1995; 25: 397-462. 770-779.
- 218) Larsen L E and Grant D. General toxicology of Mn DPDP. *Acta Radiol*. 1997; 38: 770-779.
- 219) Leblondel G and Allain P, Mn transport by Caco-2 cells. *Biol Trace Elem Res*, 1999; 67: 13-28.
- 220) Leung T K et al, Brain regional distribution of monoamine oxidase activities in postnatal development in normal and chronically Mn treated rats. *Metab Brain Dis*, 1993; 8: 137-149
- 221) Lewis J et al, Trigeminal uptake and clearance of inhaled manganese chloride in rats and mice. *Neurotoxicology*, 2005; 26: 113-123.
- 222) Li G J et al, Alterations at translational but not transcriptional level of transferrin receptor expression following Mn exposure at the blood-CSF barrier in vitro. *Toxicol Appl Pharmacol*, 2005; 205: 188-200.

- 223) Lipe G W et al, Effect of Mn on the concentrations of amino acids in different regions of the rat brain. *J Environ Sci Health B*, 1999; 34: 119-132.
- 224) Marklund S L et al, Copper and zinc containing superoxide dismutase, manganese containing superoxide dismutase, catalase and glutathione peroxidase in normal and neoplastic cell lines and normal human tissues. *Cancer Res*, 1982; 42:1955-1961.
- 225) Mergler D and Baldwin M, Early manifestations of Mn neurotoxicity in humans: an update. *Environ Res*, 1997; 73: 92-100.
- 226) Missey P et al, Effects of sub-chronic exposure to Mn chloride in tissue distribution of 3 essential elements in rats. *Int J Toxicol*, 2000; 19: 313-321.
- 227) Murphy V A et al, Saturable transport of Mn across the rat blood brain barrier. *J Neurochem*, 1991; 57: 948-954.
- 228) Newland M C, Animal models of Mn neurotoxicity. *Neurotoxicology*, 1999; 20: 415-432.
- 229) Newland M C and Weiss B, Persistent effects of Mn and effortful responding and their relationship to Mn accumulation in the primate globus pallidus, *Toxicol Appl Pharmacol*, 1992; 113: 87-97.
- 230) Normandin L and Hazell A S, Mn neurotoxicity: an update of pathophysiologic mechanisms. *Metab Brain Dis*, 2002; 17: 375-397.
- 231) Pappas B A et al, Perinatal Mn exposure: behavioural, neurochemical and histopathological effects in the rat. *Neurotoxicol-Teratol*, 1997; 19: 17-25.
- 232) Ponnappakkam T P et al, Assessment of the male reproductive system in CD-1 mice following oral Mn exposure. *Reprod Toxicol*, 2003; 17: 547-551.
- 233) Rao K V R and Norenberg M D, Mn induces the mitochondrial permeability transition in cultured astrocytes. *J Biol Chem*, 2004; 279: 32333-32338.
- 234) Roels H et al, Influence of the route of administration and the chemical form on the absorption and cerebral distribution of Mn in rats. *Arch Toxicol*, 1997; 71: 223-230.
- 235) Roth J A et al, Mechanisms of Mn induced rat pheochromocytoma (PC12) cell death and cell differentiation. *Neurotoxicology*, 2002; 23: 147-157.
- 236) Roth J A and Garrick M D, Iron interactions and other biological reactions mediating the physiological and toxic actions of Mn. *Biochem Pharmacol*, 2003; 66: 1-13.
- 237) Sanchez D J et al, Maternal and development toxicity of Mn in the mouse. *Toxicol Lett*, 1993; 69: 45-52.
- 238) Sandstroem B et al, Retention of Mn (54 Mn) in humans after intake of a labelled vitamin and mineral supplement. *J Trace Elem Electrolytes Health Dis*, 1987; 1: 33-38.
- 239) Sandstroem B et al, Effect of long term trace element supplementation on blood trace element levels and absorption of 75Se, 54Mn and 65Zn. *J Trace Elem Electrolytes Health Dis*, 1990; 4: 65-72.
- 240) Saric M and Piasek M, Environmental exposure to Mn and combined exposure gaseous upper respiratory irritants, mechanism of action and adverse health. *Rev Environ Health*, 2000; 15: 413-419.
- 241) Scheuhammer A M, Chronic Mn exposure in rats: histological changes in the pancreas. *J Tox Environ Health*, 1983; 12: 2-3.
- 242) Schrantz N et al, Mn induces apoptosis of human B cells: caspase dependant cell death blocked by bcl-2. *Cell death Differ*, 1999 ; 6: 445-453.
- 243) Shikakidze A et al, Behavioural impairment in acute and chronic Mn poisoning in white rats. *Neurosci Behav Physiol*, 2003; 33: 263-267.
- 244) Shinotoh H et al, MRI and PET studies of Mn intoxicated monkeys. *Neurology*, 1995; 45: 1199-1204.
- 245) Smorgen C et al, Trace elements and cognitive impairment. An elderly cohort study. *Arch Gerontol Geriatr*, 2004; 38suppl: 393-402.

- 246) Snyder R D and Friedman M B, Enhancement of cytotoxicity and clastogenicity of l-DOPA and dopamine by Mn and copper. *Mutat Res*, 1998; 405: 1-8.
- 247) Spector H E, in *Patty's Industrial Hygiene and Toxicology*, Ed Clayton G D and E. John Wiley & Sons, New York, 1981.
- 248) Stipanuk M H (Ed), *Biochemical and Physiological Aspects of Human Nutrition*. Saunders and Co. 2000, 742-760.
- 249) Stokes A H et al, Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis. *Brain Res*, 2000; 858: 1-8.
- 250) Takeda A et al, Biological half lives of zinc and Mn in rat brain. *Brain Res*, 1995; 695: 53-58.
- 251) Takeda A et al, Mn uptake into rat brain during development and aging. *J Neurosci Res*, 1999; 56: 93-98.
- 252) Takeda A et al, Influence of transferrin on Mn uptake in rat brain. *J Neurosci Res*, 2000; 59: 542-552.
- 253) Takser L et al, Mn, monoamine metabolite levels at birth and child psychomotor development. *Neurotoxicology*, 2003; 24: 667-674.
- 254) Torrente M et al, Effects of prenatal exposure to Mn on postnatal development and behaviour in mice: Influence of maternal restraint. *Neurotoxicol Teratol*, 2002; 24: 219-225.
- 255) Torrente M et al, Behavioural effects of adult rats concurrently exposed to high doses of oral Mn and restraint stress. *Toxicology*, 2005; 211: 59-69.
- 256) Tran T T et al (a), Effects of neonatal dietary Mn exposure in brain dopamine levels and neurocognitive functions. *Neurotoxicology*, 2002; 23: 645-651.
- 257) Tran T T et al (b), Effects of high dietary Mn intake in neonatal rats on tissue mineral accumulation, striatal dopamine levels and neurodevelopment status. *Neurotoxicology*, 2002; 23: 635-643.
- 258) Van Gossum A and Neve J, Trace element deficiency and toxicity. *Curr Opin Clin Nutr Metab Care*, 1998; 1: 499-507.
- 259) Vrcic H et al, Acute oral manganese toxicity in relation to the type of exposure. *Rad Med Fak Zagrebu*, 1988; 29: 145-148.
- 260) Weber S et al, Effects of Mn on the developing rat brain, oxidative stress related endpoints. *Neurotoxicology*, 2002; 23: 169-175.
- 261) Wiczorek H and Oberdoerster G, Kinetics of inhaled 54MnCl<sub>2</sub> aerosols: influence of inhaled concentration. *Pol J Occup Med*, 1989; 2: 248-260.
- 262) Yokel R A, Brain uptake, retention, and efflux of aluminium and Mn. *Environ Health Perspect*, 2002; 110 suppl 5; 699-704.
- 263) Yong V W et al, Chronic organic Mn administration in the rat does not damage dopaminergic nigrostriatal neurons. *Neurotoxicology*, 1986; 7: 19-24.
- 264) Yu A B C et al, An animal model for investigating Mn absorption at various regions of the gastrointestinal tract. *Drug Dev Ind Pharm*, 1994; 20: 1285-1293.
- 265) Zheng W et al, Mn inhibits mitochondrial aconitase: a mechanism of Mn neurotoxicity. *Brain Res*, 1998; 799: 334-342.
- 266) Zheng W et al, Alteration of iron homeostasis following chronic exposure to Mn in rats. *Brain Res*, 1999; 833: 125-132.
- 267) Zheng W et al, Comparative toxicokinetics of Mn chloride and methylcyclopentadienyl Mn tricarbonyl in Sprague Dawley rats. *Toxicol Sci*, 2000; 54: 295-301.
- 268) Zwingmann C et al, Brain energy metabolism in a sub acute rat model of Mn neurotoxicity. *Neurotoxicology*, 2004; 25: 573-587.

## COPPER

- 269) Abba M et al, Clastogenic effect of copper deficiency in cattle. *Mutat Res*, 2000; 466: 51-55.
- 270) Ackerman D J et al, Sperm abnormalities associated with high copper levels in impala in the Kruger National Park, South Africa. *Ecotoxicol Environ Saf*, 1999; 43: 261-266.
- 271) Agarwal K et al, Effects of copper on mammalian cell components. *Chem Biol Interact*, 1989; 69: 1-16.
- 272) Agarwal K et al, Clastogenic effects of copper sulphate on the bone marrow chromosomes of mice in vivo. *Mutat Res*, 1990; 243: 1-6.
- 273) Aggett P J, An overview of the metabolism of copper. *Eur J Med Res*, 1999; 4: 214-216.
- 274) Agte V et al, Apparent absorption of copper and zinc from composite vegetarian diets in young Indian men. *Ann Nutr Metab*, 1994; 38: 9-13.
- 275) Ahmed T et al, Acute pulmonary haemodynamic effects of intravenous copper sulphate: role of alpha adrenergic system. *J Appl Physiol*, 1981; 51: 1204-1213.
- 276) Araya M et al, Determination of an acute no observed adverse effect level for copper in water. *Regul Toxicol Pharmacol*, 2001; 34: 137-145.
- 277) Araya M et al, Confirmation of an acute no observed adverse effect and low observed adverse effect level for copper in bottled drinking water in a multi site international study. *Regul Toxicol Pharmacol*, 2003; 38: 389-399.
- 278) Araya M et al, Gastric response to acute copper exposure. *Sci Total Environ*, 2003a; 303: 253-257.
- 279) Araya M et al, Gastrointestinal symptoms and blood indicators of copper load in apparently healthy adults undergoing controlled copper exposure. *Am J Clin Nutr*, 2003b; 77: 646-650.
- 280) Araya M et al, effects of chronic copper exposure during early life in rhesus monkeys. *Am J Clin Nutr*, 2005; 81: 1065-1071.
- 281) Arredondo M et al, Regulation of copper uptake and transport in intestinal cell monolayers by acute and chronic copper exposure. *Biochim Biophys Acta*, 2000; 1474: 169-176.
- 282) Arredondo M et al, Copper overload affects copper and iron metabolism in Hep-G2 cells. *Am J Physiol Gastrointest Liver Physiol*, 2004; 287: G27-G32.
- 283) Bara M et al, relationship between magnesium, carcinogenic metals and ionic permeability of the human amnion. *Magnes Res*, 1988; 1: 231-237.
- 284) Barash A et al, Development of human embryos in the presence of a copper intrauterine device. *Gynecol Obstet Invest*, 1990; 29: 203-206
- 285) Barceloux D G, Copper. *J Toxicol Clin Toxicol*, 1999; 37: 217-230.
- 286) Bal W and Kasprzak K S, Induction of oxidative DNA damage by carcinogenic metals. *Toxicol Lett*, 2002; 127: 55-62.
- 287) Bartner R et al, Pancytopenia, arthralgia and myeloneuropathy due to copper deficiency. *Med Klin Munich*, 2005; 100: 497-501.
- 288) Bataineh H et al, Assessment of aggression, sexual behaviour and fertility in adult male rat following long term ingestion of industrial metal salts. *Hum Exp Toxicol*, 1998; 17: 570-576.
- 289) Bauerly K A et al, Effects of copper supplementation on copper absorption, tissue distribution and copper transporter expression in an infant rat model. *Am J Physiol Gastrointest Liver Physiol*, 2005; 288: G1007-G1014.

- 290) Berger M M et al, Influence of early trace element and vitamin E supplements on anti-oxidant status after major trauma. *Nutr res*, 2001; 21: 41-54.
- 291) Blincoe C, Simulation of copper metabolism by mammals. *Comput Biol Med*, 1992; 22: 113-122.
- 292) Brewer N R, Comparative metabolism of copper. *J Am Vet Med Assoc*, 1987; 190: 654-658
- 293) Chattopadhyay A et al, Antitesticular effect of copper chloride in albino rats. *J Toxicol Sci*, 1999; 24: 393-397.
- 294) Crowe A and Morgan E H , Iron and copper interact during their uptake and deposition in the brain and other organs of developing rats exposed to dietary excess of the 2 metals. *J Nutr*, 1996; 126: 183-194.
- 295) Davis C D and Feng Y, Dietary Cu, Mn and Fe affect the formation of aberrant crypts in colon of rats administered 3,2 dimethyl 4 aminobiphenyl. *J Nutr*, 1999; 129: 1060-1067.
- 296) De Oliveria J LG, A nutritious cocktail for the treatment of melanoma. A case report. *J Orthomol Med*, 1998, 13: 176-178.
- 297) Desoize B, Metals and metal compounds in carcinogenesis. *In Vivo*, 2003; 17: 529-539.
- 298) DiCarlo F J, Syndromes of cardiovascular malformations induced by copper citrate in hamsters. *Teratology*, 1980; 21: 89-101.
- 299) Dreno B et al, Study on comined treatment of recent fissures with copper gluconate and manganese gluconate. *Nouv Dermatol*, 1998; 16: 374-377.
- 300) Eife R et al, Chronic poisoning by copper in tap water II. Copper intoxications with predominantly systemic symptoms. *Eur J Med Res*, 1999; 4: 224-228.
- 301) Ferruzza S et al, Copper uptake and intracellular distribution in the human intestinal Caco-2 cell line. *Biometals*, 2000; 13: 179-185.
- 302) Fuentealba I C et al, Effect of age and sex on liver damage due to excess dietary copper in Fischer 344 rats. *J Toxicol Clin Toxicol*, 2000; 38: 709-717.
- 303) Gaetke L M and Chow C K, Copper toxicity, oxidative stress, and anti-oxidant nutrients. *Toxicology*, 2003; 189: 147-163.
- 304) Galaris D and Evangelou A, The role of oxidative stress in mechanisms of metal induced carcinogenesis. *Crit Rev Oncol Hematol*, 2002; 42: 93-103.
- 305) Geissinger H D and Robinson G A, Copper induced skeletal myopathy in rabbits. *Can J Comp Med*, 1981; 45: 97-102.
- 306) Gooneratne S R and Howell J M, Creatinine kinase release and muscle changes in chronic copper poisoning in sheep. *Res Vet Sci*, 1980; 28: 351-361.
- 307) Gotteland M et al, Effect of acute copper exposure on gastrointestinal permeability in healthy volunteers. *Dig Dis Sci*, 2001; 46: 1909-1914.
- 308) Grobber D G and Swan G E, Attempted induction of chronic copper poisoning in boma confined impala. *Onderstepoort J Vet Res*, 1999; 66: 169-174.
- 309) Gummow B, Experimentally induced chronic copper toxicity in cattle. *Onderstepoort J Vet Res*, 1996; 63: 277-288.
- 310) Gutierrez R E et al, Supersensitivity of the cholinergic muscarinic system in the rats brain is induced by high concentrations of Cu<sup>2+</sup>. *Invest Cin*, 2002; 43: 107-117.
- 311) Harada M et al, Biliary copper excretion in acutely and chronically copper loaded rats. *Hepatology*, 1993; 17: 111-117.
- 311A) Harris E D. Basic and Clinical aspects of copper. *Crit Rev Clin Lab Sci*, 2003; 40: 547-586.
- 312) Hartter D E and Barnea A, Evidence for the release of copper in the brain: depolarisation induced release of newly taken up <sup>67</sup>Cu. *Synapse*, 1988; 2: 412-415.

- 313) Hartwig A et al, Interference by toxic metal ions with zinc dependant proteins involved in maintaining genomic stability. *Food Chem Toxicol*, 2002; 40: 1179-1184.
- 314) Hebert C D et al, Sub-chronic toxicity of cupric sulphate administered in drinking water mand feed to rats and mice. *Fundam Appl Toxicol*, 1993; 21: 461-475.
- 315) Hiraku Y et al, Metal mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. *Carcinogenesis*, 1995; 16: 349-356.
- 316) Hirano S et al, Metabolism and pulmonary toxicity of intratracheally instilled copper sulphate in rats. *Toxicology*, 1990; 64: 223-233.
- 317) Hirano S et al, Pulmonary clearance and toxicity of intracheally instilled cupric oxide in rats. *Arch Toxicol*, 1993; 67: 312-317.
- 318) Houwen R et al, Two pathways for biliary copper excretion in the rat. The role of glutathione. *Biochem Pharmacol*, 1990; 39: 1039-1044.
- 319) Humann Z E et al, Long term observations of subclinical chronic copper poisoning in 2 sheep breeds. *J Vet Med A Physiol Pathol Clin Med*, 2001; 48: 429-439.
- 320) Hunt J R and Vanderpool R A, Apparent copper absorption from a vegetarian diet. *Am J Clin Nutr*, 2001; 74: 803-807.
- 321) Jacob R A et al, Effect of varying ascorbic acid intakes on copper absorption and ceruloplasmin levels of young men. *J Nutr*, 1987; 117: 2109-2115.
- 322) Jamali B et al, Spring time and Autumn time toxic effects of copper (II), 3-(2-furyl) prop-2-enal semicarbazone and CuCl<sub>2</sub> complex in mice. *Biol Rhythm-Res*, 1998; 29: 229-236.
- 323) Jimenez I et al, Chronic exposure of HepG2 cells to excess copper results in depletion of glutathione and induction of metallothionein. *Toxicol in vitro*, 2002; 16: 167-175.
- 324) Johnson P E et al, Bioavailability of copper to rats from various foodstuffs, and in the presence of different carbohydrates. *Proc Soc Exp Biol Med*, 1988; 187: 44-50.
- 325) Johnson P E et al, Effects of age and sex on copper absorption, biological half- life and status in humans. *Am J Clin Nutr*, 1992; 56: 917-925.
- 326) Kies C and Harms J M, Copper absorption as affected by supplemental calcium, magnesium, manganese, selenium and potassium. *Adv Exp Med Biol*, 1989; 258: 45-58.
- 327) Kowalik J T et al, Possible involvement of copper in Alzheimers disease. *Environ Health Perspect*, 2002; 110: 869-870.
- 328) Kumaratilake J S and Howell J M, Intracellular distribution of copper in the liver of copper loaded sheep-a subcellular fractionation study. *J Comp Pathol*, 1989; 101: 161-176.
- 329) Kvietkauskaitė R et al, Effect of low copper exposure on the anti-oxidant system and some immune parameters. *Vet Hum Toxicol*, 2004; 46: 169-172.
- 330) Lee S H et al, Ceruloplasmin and copper transport during the latter part of gestation in the rat. *Proc Soc Exp Biol Med*, 1993; 203: 428-439.
- 331) Levenson C W, Mechanisms of copper conservation in organs. *Am J Clin Nutr*, 1998; 67: 978S-981S.
- 332) Liang R et al, Effects of Ni (II) and Cu (II) on DNA interaction with the N-terminal sequence of human protamine P2: enhancement of binding and mediation of oxidative DNA strand scission and base damage. *Carcinogenesis*, 1999; 20: 893-898.
- 333) Linder M C et al, Copper transport. *Am J Clin Nutr*, 1998; 67: 965S-971S.
- 334) Llanos R M and Mercer J C B, The molecular basis of copper homeostasis and copper related disorders. *DNA Cell Biol*, 2002; 21: 259-270.
- 335) Lin C et al, Oxidative stress is involved in inhibition of copper on histone acetylation in cells. *Chem Biol Interact*, 2005; 151: 167-176.
- 336) Linder M C, Copper and genomic stability in mammals. *Mutat Res*, 2001; 475: 141-152.

- 337) Loennerdal B, Copper nutrition during infancy and childhood. *Am J Clin Nutr*, 1998, 67: 1046S-1053S. (see ref 224)
- 338) Laudanski T et al, Influence of copper ions on uterine activity. *Contraception*, 1981; 24: 195-202.
- 339) Mallet V and Lemarchand V F, Means of cutaneous healing. *Rev Prat*, 1994; 44: 1781-1785.
- 340) Mandigers P J J et al, Chronic hepatitis in Doberman Pinschers: A review. *Vet Q*, 2004; 26: 98-106.
- 341) Mann J and Truswell A S (Eds), *Essentials of Human Nutrition*. Oxford University Press, 2002.
- 342) Marklund S L et al, Copper and zinc containing superoxide dismutase, manganese containing superoxide dismutase, catalase and glutathione peroxidase in normal and neoplastic cell lines and normal human tissues. *Cancer Res*, 1982; 42:1955-1961.
- 343) Mason R W et al, Teratogenicity of combinations of sodium dichromate, sodium arsenate, and copper sulphate in the rat. *Comp Biochem Physiol*, 1989; 93: 407-411
- 344) Massanyi P et al, Concentration of copper, iron, zinc, cadmium, lead and nickel in bull and ram semen, and relation to the occurrence of pathological spermatazoa. *J Environ Sci Health. Part A Toxic Hazard Subs Environ Eng*, 2004; 39: 3005-3014.
- 345) Menino A R et al, The influence of dietary copper on reproduction, growth and the cardiovascular system in Swiss-Webster female rats. *Lab Animal Sci*, 1986; 36: 164-167.
- 346) Mizejewski G J et al, Effects of heavy metals on alpha-fetoprotein in maternal sera and amniotic fluid of pregnant mice, 1990; 64: 19-32.
- 347) Mueller T et al, The canine copper toxicosis gene MURR1 does not cause non-Wilsonian hepatic copper toxicosis, *J Hepatol*, 2003; 38: 164-168.
- 348) Nandakumaran M et al, Transport kinetics of zinc, copper, selenium and iron in perfused human placental lobule in vitro. *Mol Cell Biochem*, 2003; 252: 91-96.
- 349) Nederbragt H et al, Pathology of copper toxicity. *Vet Q*, 1984; 6: 179-185.
- 349A) Nieper H A. The non-toxic, long- term therapy of cancer: Necessity, state of the art, trends. *Int Acad Preventive Med*, 1979; 6: 41-70
- 350) O'Dell B L, Dietary carbohydrate source and copper bioavailability. *Nutr Rev*, 1990; 8: 425-434.
- 351) Olin K L et al, The effects of some redox active metals and reactive aldehydes on DNA protein cross links in vitro. *Toxicology*, 1996; 110: 1-8.
- 352) Olivares M et al, Age and copper intake do not affect copper absorption. *Am J Clin Nutr*, 2002; 76: 641-645.
- 353) Ortolani E L et al, Acute sheep poisoning from a copper sulphate foot bath. *Vet Hum Toxicol*, 2004; 46: 315-318.
- 354) Pan Y and Loo G, Effect of copper deficiency on oxidative DNA damage in Jurkat T lymphocytes. *Free Radic Biol Med*, 2000; 28: 824-830.
- 355) Pandit A N, and Bhawe S A, Copper metabolic defects and liver disease: Environmental aspects. *J Gastroenterol Hepatol*, 2002; 17: S403-S407.
- 356) Percival S S and Harris E D, Copper transport from cerloplasmin: Characterisation of the cellular uptake mechanism. *Am J Physiol*, 1990; 258: C140-C146.
- 357) Pettersson R et al, Copper in drinking water: not a strong risk factor for diarrhoea among young children. A population based study from Sweden. *Acta Paediatr*, 2003; 92: 473-480.
- 358) Pirot F et al, Simultaneous absorption of copper and zinc through human skin in vitro: influence of counter ion and vehicle. *Skin Pharmacol*, 1996; 9: 43-52.
- 359) Pizarro F et al, Acute gastrointestinal effects of graded levels of copper in drinking water. *Environ Health Perspect*, 1999; 107: 117-121.

- 360) Pourahmad J et al, Carcinogenic metal induced sites of reactive oxygen species formation in hepatocytes. *Toxicol Vitro*, 2003; 17: 803-810.
- 361) Pratt W B et al, Treatment of back pain with copper supplementation. *Trace Elem Med*, 1985; 2: 155-157.
- 362) Rhee H M and Dunlap M, Acute cardiovascular toxic effects of copper in anaesthetised rabbits. *Neurotoxicology*, 1990; 11: 355-360.
- 363) Rojas L X, Interaction of different organic and inorganic zinc and copper sources fed to rats. *J Trace Elem Med Biol*, 1996; 10: 139-144.
- 364) Rosado J L, Zinc and copper proposed fortification levels and recommended zinc compounds. *J Nutr*, 2003; 133: 2985S-2989S.
- 365) Rossman T G, On the mechanism of the comutagenic effect of Cu(II) with ultraviolet light, 1989; 21: 383-388.
- 366) Rusanov E M et al, Effect of chronic copper loading on the activity of rat liver anti-oxidative enzymes. *Acta Physiol Pharmacol Bulg*, 1986; 12: 51-56.
- 367) Saleha B B et al, DNA damage in leukocytes of mice treated with copper sulphate. *Food Chem Toxicol*, 2004; 42: 1931-1936.
- 368) Sandstead H H, Requirements and toxicity of essential trace elements, illustrated by Zinc and Copper. *Am J Clin Nutr*, 1995; 61: 621S-624S.
- 369) Sangripanti J L et al, Interaction of copper with DNA and antagonism by other metals. *Toxicol Appl Pharmacol*, 1991; 110: 477-485.
- 370) Sansinanea A S et al, Glucose-6-phosphate dehydrogenase activity in erythrocytes from chronically copper poisoned sheep. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol*, 1996; 114: 197-200.
- 371) Schuemann K et al, Hohenheim consensus workshop: copper. *Eur J Clin Nutr*, 2002; 56: 469-483.
- 372) Schmidt C M et al, Hormesis effect of trace metals on cultured normal and immortal human mammary cells. *Toxicol Ind Health*, 2004; 20: 57-68.
- 373) Senesse P et al, High dietary iron and copper risk of colorectal cancer: a case control study in Burgundy, France. *Nutr Cancer*, 2004; 49: 66-71.
- 374) Sheline C and Choi D W, Cu<sup>2+</sup> toxicity inhibition of mitochondrial dehydrogenase in vitro and in vivo. *Ann Neurol*, 2004; 55: 645-653.
- 375) Shinar E et al, Oxidative damage to human red cells induced by copper and iron complexes in the presence of ascorbate. *Biochim Biophys Acta*, 1989; 1014: 66-72.
- 376) Sideris E G et al, Mutagenesis, carcinogenesis and the metal elements-DNA interaction. *Prog Clin Biol Res*, 1988; 259: 13-25. (see ref 248)
- 377) Skandhan K P, Review on copper in male reproduction and contraception. *Rev Fr Gynecol Obstet*, 1992; 87: 594-598.
- 378) Smorgen C et al, Trace elements and cognitive impairment. An elderly cohort study. *Arch Gerontol Geriatr*, 2004; 38suppl: 393-402.
- 3879) Spector W S (Ed), *Handbook of Toxicology*, Saunders, Philadelphia, 1956; 1: 182-182
- 380) Stipanouk M H. Ed, *Biochemical and Physiological Aspects of Human Nutrition*, Saunders and Co, 2000; 742-759.
- 381) Stokinger H E in *Patty's Industrial Hygiene and Toxicology*, Ed Clayton G D and E, John Wiley and Sons, New York, 1981
- 382) Strubelt O et al, Comparative studies on the toxicity of mercury, cadmium, and copper toward the isolated perfused rat liver. *J Toxicol Environ Health*, 1996; 47: 267-283.
- 383) Sugawara N et al, Response of hepatic function to hepatic copper deposition in rats fed a diet containing copper. *Biol Trace Elem Res*, 1995; 49: 161-169.

- 384) Tao T Y et al, the copper toxicosis gene product MURR1 directly interacts with the Wilson disease protein. *J Biol Chem*, 2003; 278: 41593-41596.
- 385) Tapia L et al, Metallothionein is crucial for safe intracellular copper storage and cell survival at normal and supra-physiological exposure levels. *Biochem J*, 2004; 378: 617-624.
- 386) Toyokuni S and sagripanti J L, Increased 8-hydroxydeoxyguanosine in kidney and liver of rats continuously exposed to copper. *Toxicol Appl Pharmacol*, 1994; 126: 91-97.
- 387) Tsang S Y et al, Copper-1,10 phenanthroline induces internucleosomal DNA fragmentation in HepG2 cells resulting from direct oxidation by the hydroxyl radical. *Biochem J*, 1996; 317: 13-16.
- 388) Turnlund J R et al, Iron and copper absorption in young and elderly men. *Nutr Res*, 1988; 8: 333-343.
- 389) Turnlund J R et al, A stable isotope study of zinc, copper and iron absorption and retention by young women fed vitamin B6 deficient diets. *Am J Clin Nutr*, 1991; 54: 1059-1064.
- 390) Velez-Pardoe C et al, Mn and Cu promote the binding of dopamine to serotonin binding proteins in bovine frontal cortex. *Neurochem Int*, 1995; 26: 615-622.
- 391) Videla L A et al, Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells. *Biometals*, 2003; 16: 103-111.
- 392) Zietz B R et al, Epidemiological investigation on chronic copper toxicity to children exposed via the public drinking water supply. *Sci Total Environ*, 2003; 302: 127-144.